Angiogenesis as a therapeutic target

@article{Ferrara2005AngiogenesisAA,
  title={Angiogenesis as a therapeutic target},
  author={Napoleone Ferrara and Robert S. Kerbel},
  journal={Nature},
  year={2005},
  volume={438},
  pages={967-974}
}
Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of… 
Antiangiogenesis to treat cancer and intraocular neovascular disorders
TLDR
Progress in targeting one of the major regulators of angiogenesis, VEGF-A, is focused on, and potential cellular and molecular mechanisms underlying resistance to antiangiogenic treatments are discussed.
Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases.
TLDR
The main strategies developed for anti-angiogenic therapies beside their clinical applications, the major challenges, and the latest advances in the development of anti-Angiogenesis-based targeted therapies are reviewed.
Antiangiogenic Therapy for Cancer: An Update
TLDR
Clinical progress in targeting one of the major regulators of angiogenesis, vascular endothelial growth factor-A, is focused on and some recent advances in the elucidation of potential cellular and molecular mechanisms underlying refractoriness or resistance to antiangiogenic therapies are discussed.
Targeting VEGF-A to treat cancer and age-related macular degeneration.
TLDR
This review summarizes the basic biology of VEGF-A and illustrates the clinical progress in targeting this molecule and describes the neovascular form of age-related macular degeneration.
Emerging technologies for enabling proangiogenic therapy.
TLDR
Various protein engineering strategies to develop stabilized proangiogenic proteins and several biomaterial technologies used to amplify the angiogenic outcome by delivering biologically active growth factors in a sustained manner are discussed.
Pathophysiology and Clinical Implications of Vascular Endothelial Growth Factor
TLDR
This chapter summarizes the basic biology of VEGF-A and illustrates the clinical progress in targeting this molecule, which resulted in a therapeutic benefit in a variety of models of cancer and intraocular neovascular syndromes.
VEGF inhibition: insights from preclinical and clinical studies
TLDR
This review examines the various mouse tumor models in which VEGF inhibitors have been tested and the lessons learned from these studies.
Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
TLDR
The biological mechanisms which underlie the role of angiogenesis in breast cancer carcinogenesis are described, its contribution to the metastatic process is depicted and the immunologic role of VEGF deserves to be further explored.
Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
  • Yihai Cao
  • Medicine
    Advances in cancer research
  • 2008
Bevacizumab (Avastin), a vascular endothelial growth factor antagonist, is the first approved antiangiogenic drug for the treatment of human cancers. Endostatin, a broad-spectrum endogenous
Hypoxia, angiogenesis, and colorectal cancer
The induction of angiogenesis is a nearly universal feature of solid malignancies, and therapeutic strategies that specifically inhibit this process have now entered the clinical arena. Colorectal
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 110 REFERENCES
Clinical applications of angiogenic growth factors and their inhibitors
TLDR
Inhibition of the action of key regulators of angiogenesis, such as VEGF, constitutes a promising approach for the treatment of solid tumors and intraocular neovascular syndromes.
Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.
When first conceived, antiangiogenic therapy for cancer offered the possibility of universal efficacy, low toxicity, and little possibility of resistance. Blockade of the vascular endothelial growth
Combination of Antiangiogenic Therapy With Other Anticancer Therapies: Results, Challenges, and Open Questions
TLDR
Preliminary results of the clinical studies suggest that single-agent antiangiogenic therapy is poorly active in advanced tumors.
Clinical translation of angiogenesis inhibitors
TLDR
Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply, and clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians.
Vascular‐targeting therapies for treatment of malignant disease
TLDR
The goal of these approaches is to induce a rapid and catastrophic shutdown of the vascular function of the tumor so that blood flow is arrested and tumor cell death due to the resulting oxygen and nutrient deprivation and buildup of waste products occurs.
The biology of VEGF and its receptors
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
TLDR
The recent approval of bevacizumab by the US FDA as a first-line therapy for metastatic colorectal cancer validates the ideas that VEGF is a key mediator of tumour angiogenesis and that blockingAngiogenesis is an effective strategy to treat human cancer.
Angiogenesis: where do we stand now?
TLDR
Some of the current understanding of the regulation of blood vessel growth in mature adult tissues and the various therapeutic applications of this knowledge are examined.
Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
TLDR
An overview of experimental and clinical studies of combined therapy with antiangiogenic agents is presented and the challenges related to the appropriate strategies for selection of the patients, study design, and choice of proper end points for preclinical andclinical studies using these agents are highlighted.
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2.
TLDR
Anti-Ang2 therapy prevented VEGF-stimulated neovascularization in a rat corneal model of angiogenesis and implies that specific Ang2 inhibition may represent an effective antiangiogenic strategy for treating patients with solid tumors.
...
1
2
3
4
5
...